Avivagen Attending New England Pet Expo
18 Septembre 2013 - 2:00PM
Access Wire
OTTAWA, ONTARIO, (Accesswire - September 18, 2013) - Avivagen
Inc. (TSXV:VIV), a wellness company developing and delivering
products that support and enhance the health and quality of life
for animals and the people who care for them, announces that it
will be attending the New England Pet Expo on September 21st.
The New England Pet Expo is held at the Aleppo Shriner's
Auditorium in Wilmington, Massachusetts - a suburb of Boston. The
exposition showcases pet-related products and services, with over
125 exhibitors, and is attended by thousands of caregivers and
their pets.
Avivagen will be showcasing its Vivamune(TM) Health Chews for
Large Dogs, Small Dogs and Cats at the exposition. Staff will be
on-hand to explain the health benefits of the Company's proprietary
fully-oxidized carotenoid technologies, to address product-related
questions and build product awareness.
Attendance at such pet-oriented expositions is an important
component of Avivagen's marketing strategy, as it lets pet parents
see Vivamune(TM) Health Chews first-hand and meet representatives
of the Company. Avivagen will be attending further pet-related
expositions through the rest of 2013 and into 2014 as it rolls-out
a multi-faceted marketing strategy for its Vivamune(TM) companion
animal brand.
For further information about the New England Pet Expo, please
visit http://www.newenglandpetexpo.com/
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life sciences company trading
on the TSX Venture Exchange under the ticker symbol "VIV". The
Company's goal is to develop and deliver scientifically-proven
solutions that can truly benefit companion and production animals
by employing natural mechanisms for maintaining good health.
Avivagen's targeted markets include Pet Wellness and Livestock
Productivity.
The company has sites located in partnership facilities of the
National Research Council of Canada (NRC) - in Ottawa, Ontario and
Charlottetown, Prince Edward Island. More information can be found
at www.avivagen.com.
About OxC-beta
Avivagen's proprietary and patent-protected technology is based
on its discoveries concerning carotenoid antioxidants. The novel
natural compounds discovered by Avivagen support the body's own
systems to maintain and enhance health, particularly by supporting
immune function. Avivagen's first application of its technology is
Fully-Oxidized beta-Carotene (OxC-beta). OxC-beta compounds occur
naturally as carotenoid oxidation products in vegetation, but in
minute amounts. They have been developed to support the health of
companion animals and for use in the global food animal market.
Research results indicate OxC-beta supports innate immune
function, which can help maintain good health. In pets, OxC-beta
supports overall vitality and energy, mobility and joint function,
skin, coat and gut. Results observed in food animals have included
healthier growth, better utilization of feed and decreased
mortality. In food animals, it is intended that use of OxC-beta
avoids the feeding of antibiotics.
The commercial products of Avivagen are Oximunol(TM) Chewables,
OxC-beta for livestock and Vivamune(TM) Health Chews.
About Vivamune(TM) Health Chews - "For dogs that dig life" and
"For extraordinary cats"
Vivamune(TM) Health Chews, containing Avivagen's proprietary
active ingredients, are scientifically-formulated chews for dogs
and cats. Vivamune(TM) Health Chews work with a pet's own immune
system to maintain overall health and well-being. They are sold in
re-sealable packages of 30 chews and are currently available in the
United States by ordering on-line at www.vivamunehealth.com.
About Oximuno(TM) Chewables - "Optimized Health in a Chewable
Tablet"
Oximunol(TM) Chewables are scientifically-formulated chewable
tablets that contain Avivagen's proprietary, patented active
ingredient OxC-beta. OxC-beta has been shown to stimulate innate
cellular immunity and may thereby help to maintain overall health
and well-being. Oximunol(TM) Chewables are distributed by Bayer
Healthcare LLC and are available through veterinarians for dogs of
all ages in the United States.
About OxC-beta for Livestock
OxC-beta for Livestock is available as a 10% pre-mix sold in 1.0
or 5.0 Kg quantities for parts-per-million addition to animal
feeds, in accordance with producer-developed protocols. In past
studies, OxC-beta has been shown to support health and growth in
species such as fish, chicken, pigs and cattle. OxC-beta for
livestock is currently available for commercial sale in the Kingdom
of Thailand.
Forward Looking Statements
This news release includes certain forward-looking statements that
are based upon current expectations, which involve risks and
uncertainties associated with the business of Avivagen Inc. and the
environment in which the business operates. Any statements
contained herein that are not statements of historical facts may be
deemed to be forward-looking, including those identified by the
expressions "will", "anticipate", "believe", "plan", "estimate",
"expect", "intend", and similar expressions. The forward-looking
statements reflect the current expectations of Avivagen Inc.
regarding future results or events. These forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results or events to differ materially from
current expectations. Avivagen assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those reflected in the forward-looking
statements.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
For more information:
Avivagen Inc.
Cameron Groome
CEO & President
Phone: 613-949-8164
c.groome@avivagen.com
Avivagen (TSXV:VIV)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Avivagen (TSXV:VIV)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024